Role of CB2 receptors in social and aggressive behavior in male mice.
BACKGROUND
Male CB1KO mice exhibit stronger aggressive responses than wild-type mice.


OBJECTIVE
This study was designed to examine the role of cannabinoid CB2r in social and aggressive behavior.


METHODS
The social interaction test and resident-intruder paradigm were performed in mice lacking CB2r (CB2KO) and in wild-type (WT) littermates. The effects of the CB2r selective agonist JWH133 (1 and 2 mg/kg) on aggression were also evaluated in Oncins France 1 (OF1) mice. Gene expression analyses of monoamine oxidase-A (MAO-A), catechol-o-methyltransferase (COMT), 5-hydroxytryptamine transporter (5-HTT), and 5-HT1B receptor (5HT1Br) in the dorsal raphe nuclei (DR) and the amygdala (AMY) were carried out using real-time PCR.


RESULTS
Group-housed CB2KO mice exhibited higher levels of aggression in the social interaction test and displayed more aggression than resident WT mice. Isolation increased aggressive behavior in WT mice but did not affect CB2KO animals; however, the latter mice exhibited higher levels of social interaction with their WT counterparts. MAO-A and 5-HTT gene expression was significantly higher in grouped CB2KO mice. The expression of 5HT1Br, COMT, and MAO-A in the AMY was more pronounced in CB2KO mice than in WT counterparts. Acute administration of the CB2 agonist JWH133 significantly reduced the level of aggression in aggressive isolated OF1 mice, an effect that decreased after pretreatment with the CB2 receptor antagonist AM630.


CONCLUSIONS
Our results suggest that CB2r is implicated in social interaction and aggressive behavior and deserves further consideration as a potential new target for the management of aggression.
Unidad de Investigación Psicobiología de las Drogodependencias, Departamento de Psicobiología, Facultad de Psicología, Universitat de València, Avda. Blasco Ibáñez, 21, 46010, Valencia, Spain, marta.rodriguez@uv.es.
Marta
M
Rodríguez-Arias
Francisco
F
Navarrete
M Carmen
MC
Blanco-Gandia
M Carmen
MC
Arenas
María A
MA
Aguilar
Adrián
A
Bartoll-Andrés
Olga
O
Valverde
José
J
Miñarro
Jorge
J
Manzanares
D000374:Aggression / Q000187:drug effects / Q000502:physiology*; D000679:Amygdala / Q000378:metabolism; D000818:Animals; D063386:Cannabinoid Receptor Agonists / Q000494:pharmacology; D002186:Cannabinoids / Q000494:pharmacology; D002394:Catechol O-Methyltransferase / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D007211:Indoles / Q000494:pharmacology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008995:Monoamine Oxidase / Q000235:genetics / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D044302:Receptor, Serotonin, 5-HT1B / Q000235:genetics / Q000378:metabolism; D012701:Serotonin / Q000494:pharmacology; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism; D012919:Social Behavior
D063386:Cannabinoid Receptor Agonists; D002186:Cannabinoids; D007211:Indoles; D043885:Receptor, Cannabinoid, CB2; D044302:Receptor, Serotonin, 5-HT1B; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins; D012701:Serotonin; D008995:Monoamine Oxidase; D002394:Catechol O-Methyltransferase; C432747:1,1-dimethylbutyl-1-deoxy-Delta(9)-THC; C094023:iodopravadoline